C-erbB-2 CEA and CA 15.3 serum levels in the early diagnosis of recurrencein breast cancer patients

Citation
R. Molina et al., C-erbB-2 CEA and CA 15.3 serum levels in the early diagnosis of recurrencein breast cancer patients, ANTICANC R, 19(4A), 1999, pp. 2551-2555
Citations number
32
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTICANCER RESEARCH
ISSN journal
0250-7005 → ACNP
Volume
19
Issue
4A
Year of publication
1999
Pages
2551 - 2555
Database
ISI
SICI code
0250-7005(199907/08)19:4A<2551:CCAC1S>2.0.ZU;2-T
Abstract
C-erbB-2 CEA and CA 15.3 serial serum determinations were performed in 250 patients (follow-up: 1-4 years, mean 2.5 years) with primary breast cancer and no evidence of residual disease (NED) after radical treatment (radical mastectomy or simple mastectomy and radiotherapy). Ninety-five patients dev eloped metastases during follow-up. Results: Abnormal c-erbB-2, CEA and CA 15.3 serum levels (>20 U/ml, >10 ng/ml or >60 U/ml, respectively) prior to diagnosis were found in 28.4%, 31.6% and 46.3% of the 95 patients with recu rrence with a lead time of 4.2 +/- 2.4, 5.0 +/- 2.5 and 4.6 +/- 2.7 months, respectively. One of the tumor markers was the first sign of recurrence in 69.5% of the patients. Tumor marker specificity was 100% with levels lower than the cut-point in all 155 patients without recurrence. Tumor marker se nsitivity was clearly related to the site of recurrence with the lowest sen sitivity found in locoregional relapse and the highest in patients with liv er or bone metastases. C-erbB-2 sensitivity in early diagnosis was signific antly higher in patients with c-erbB-2 overexpression in tissue (10/12, 83. 3%) than in those without overexpression (1/34, 2.9%) (p = 0.0001). likewis e higher levels of both, c-erbB-2 and CA 15.3 at diagnosis of recurrence hi gher sensitivity in early diagnosis of relapse and a higher lead time were found in PgR+ patients (CA 15.3) or in PgR- patients (C-erbB-2) (p < 0.015) . In conclusion,tumor markers are useful tools for the early diagnosis of m etastases, being the first sign of recurrence in 69.5% of patients with rel apse (76.3% in patients with metastases).